Safety and efficacy of sorafenib in patients with hepatocellular carcinoma (HCC) and Child-Pugh A versus B cirrhosis

Gastrointestinal Cancer Research

Volumn 4, Issue 2, 2011, Pages 40-44

  Abou Alfa, Ghassan K ^a   Amadori, Dino ^b   Santoro, Armando ^c   Figer, Arie ^d   de Greve, Jacques ^e   Lathia, Chetan ^f   Voliotis, Dimitris ^f   Anderson, Sibyl ^f   Moscovici, Marius ^g   Ricci, Sergio ^h  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MORGAGNI PIERANTONI HOSPITAL   (Italy)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^e UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^f BAYER CORPORATION   (United States)

^g Bayer SpA Italy   (Italy)

^h SANTA CHIARA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCURONOSYLTRANSFERASE 1A1; SORAFENIB;

ADULT; AGED; ALOPECIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASCITES; BRAIN DISEASE; CANCER PATIENT; CONTROLLED STUDY; DATA ANALYSIS; DESQUAMATION; DETERIORATION; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; ENZYME INHIBITION; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; RETROSPECTIVE STUDY; SINGLE BLIND PROCEDURE; STOMATITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; VOMITING;

EID: 80053041858     PISSN: 19347820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390, 2008
2. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60:646-649, 1973
3. Child CG III. The Liver and Portal Hypertension. Philadelphia, PA; WB Saunders. 1964:50
4. US Food and Drug Administration. Sorafenib. Nov 20, 2007. Available at: http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm129234.htm. Accessed October 10, 2009
5. Kane RC, Farrell AT, Madabushi R, et al: Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist 14:95-100, 2009
6. Abou-Alfa GK, Schwartz L, Ricci S, et al: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:1-8, 2006
7. Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K: Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 99:159-165, 2008
8. Miller AA, Murry DJ, Owzar K, et al: Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 27:1800-1805, 2009
9. Miners JO, Mackenzie PI: Drug glucuronidation in humans. Pharmacol Ther 51:347-369, 1991
10. National Cancer Institute. Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment with Sorafenib. March 18, 2009. Available at: http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid_631237&version_HealthProfessional&protocolsearchid_6854751. Accessed April 19, 2011